CN111514473A - A method of radiation therapy for cancer cells - Google Patents
A method of radiation therapy for cancer cells Download PDFInfo
- Publication number
- CN111514473A CN111514473A CN202010196882.9A CN202010196882A CN111514473A CN 111514473 A CN111514473 A CN 111514473A CN 202010196882 A CN202010196882 A CN 202010196882A CN 111514473 A CN111514473 A CN 111514473A
- Authority
- CN
- China
- Prior art keywords
- cancer cells
- solution
- particles
- patient
- cleaning
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 29
- 238000000034 method Methods 0.000 title claims abstract description 28
- 201000011510 cancer Diseases 0.000 title claims abstract description 26
- 238000001959 radiotherapy Methods 0.000 title claims abstract description 21
- 239000002245 particle Substances 0.000 claims abstract description 34
- 239000000463 material Substances 0.000 claims abstract description 20
- 230000002285 radioactive effect Effects 0.000 claims abstract description 17
- 238000004140 cleaning Methods 0.000 claims abstract description 12
- 238000005859 coupling reaction Methods 0.000 claims abstract description 9
- 229920000642 polymer Polymers 0.000 claims abstract description 9
- 238000001948 isotopic labelling Methods 0.000 claims abstract description 7
- 238000002360 preparation method Methods 0.000 claims abstract description 7
- 125000000524 functional group Chemical group 0.000 claims abstract description 5
- 238000002560 therapeutic procedure Methods 0.000 claims abstract description 5
- 230000008878 coupling Effects 0.000 claims abstract description 4
- 238000010168 coupling process Methods 0.000 claims abstract description 4
- 230000005251 gamma ray Effects 0.000 claims abstract description 4
- 239000000243 solution Substances 0.000 claims description 38
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 12
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 10
- 229910052740 iodine Inorganic materials 0.000 claims description 10
- 239000011630 iodine Substances 0.000 claims description 10
- 229920001661 Chitosan Polymers 0.000 claims description 7
- 239000007822 coupling agent Substances 0.000 claims description 7
- 230000005855 radiation Effects 0.000 claims description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- 239000007864 aqueous solution Substances 0.000 claims description 5
- 238000002791 soaking Methods 0.000 claims description 4
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 claims description 3
- 229920001577 copolymer Polymers 0.000 claims description 3
- 230000004048 modification Effects 0.000 claims description 3
- 238000012986 modification Methods 0.000 claims description 3
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 3
- 239000004626 polylactic acid Substances 0.000 claims description 3
- 229920002635 polyurethane Polymers 0.000 claims description 3
- 239000004814 polyurethane Substances 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims 1
- 238000003756 stirring Methods 0.000 claims 1
- 239000000758 substrate Substances 0.000 abstract description 10
- 230000004060 metabolic process Effects 0.000 abstract description 3
- 230000009286 beneficial effect Effects 0.000 abstract description 2
- 238000006243 chemical reaction Methods 0.000 abstract description 2
- 238000002347 injection Methods 0.000 abstract 1
- 239000007924 injection Substances 0.000 abstract 1
- 238000005516 engineering process Methods 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 238000013170 computed tomography imaging Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
- A61N5/1002—Intraluminal radiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/06—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
- A61N5/1007—Arrangements or means for the introduction of sources into the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
- A61N5/1014—Intracavitary radiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
- A61N2005/1019—Sources therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N2005/1092—Details
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Radiology & Medical Imaging (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Optics & Photonics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Radiation-Therapy Devices (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明公开了一种用于癌细胞的放射治疗方法，包括放射性粒子制备、清洗、偶联化、同位素标记、粒子注入患者体内和伽玛射线治疗。本发明的有益效果是：采用与生物相容性较好的高分子可降解材料作为粒子基材，在注入人体内易分解，随着人的新陈代谢排除，减少对患者身体的损害，且保证基材在后续操作过程中结构的稳定性，对制备的基材进行接枝清洗和偶联化反应，去除基材表面游离的官能团，便于放射性同位素对基材进行置换反应，从而确保其注入人体后会精准对癌细胞进行定位，方便伽玛射线的集中清理，提高该治疗方法的安全性，减少其对安全正常细胞灭杀的可能性，提高该方法的操作安全性，并在一定程度上减少患者体内癌细胞的残余量。
The invention discloses a radiotherapy method for cancer cells, including radioactive particle preparation, cleaning, coupling, isotope labeling, particle injection into a patient's body and gamma ray therapy. The beneficial effects of the present invention are as follows: a polymer degradable material with good biocompatibility is used as the particle base material, which is easily decomposed when injected into the human body, and is eliminated with the human metabolism, thereby reducing the damage to the patient's body, and ensuring the basic In order to ensure the stability of the structure of the material in the subsequent operation process, the prepared substrate is subjected to graft cleaning and coupling reaction to remove the free functional groups on the surface of the substrate, which is convenient for the replacement reaction of the substrate by radioisotopes, so as to ensure that the substrate is injected into the human body. It will accurately locate cancer cells, facilitate the centralized cleaning of gamma rays, improve the safety of the treatment method, reduce the possibility of killing normal cells, improve the operational safety of the method, and reduce to a certain extent. The residual amount of cancer cells in the patient's body.
Description
技术领域technical field
本发明涉及一种治疗方法，具体为一种用于癌细胞的放射治疗方法，属于癌细胞治疗技术领域。The invention relates to a treatment method, in particular to a radiation treatment method for cancer cells, and belongs to the technical field of cancer cell treatment.
背景技术Background technique
肿瘤放射治疗是利用放射线治疗肿瘤的一种局部治疗方法。放射线包括放射性同位素产生的α、β、γ射线和各类x射线治疗机或加速器产生的x射线、电子线、质子束及其他粒子束等，大约70%的癌症患者在治疗癌症的过程中需要用放射治疗，约有40%的癌症可以用放疗根治。放射治疗在肿瘤治疗中的作用和地位日益突出，已成为治疗恶性肿瘤的主要手段之一。Tumor radiation therapy is a local treatment method that uses radiation to treat tumors. Radiation includes alpha, beta, and gamma rays produced by radioisotopes and x-rays, electron rays, proton beams, and other particle beams produced by various x-ray therapy machines or accelerators. About 70% of cancer patients require cancer treatment. About 40% of cancers can be cured with radiation therapy. The role and status of radiotherapy in tumor treatment has become increasingly prominent, and it has become one of the main means of treating malignant tumors.
放射疗法虽仅有几十年的历史，但发展较快，在CT影像技术和计算机技术发展帮助下，现在的放疗技术由二维放疗发展到三维放疗、四维放疗技术，放疗剂量分配也由点剂量发展到体积剂量分配，及体积剂量分配中的剂量调强。Although radiotherapy has a history of only a few decades, it has developed rapidly. With the help of CT imaging technology and computer technology, the current radiotherapy technology has developed from two-dimensional radiotherapy to three-dimensional radiotherapy and four-dimensional radiotherapy. Dose progression to volumetric dosing, and dose modulation in volumetric dosing.
但是现有的治疗方法虽然有效，但是其有时会对正常细胞进行杀伤，精准度还不够高，且放疗根治的成功率存在提升空间，而其在抗癌药物剂量分配上需要更加精细化处理，且现有的方法一些粒子对人体存在危害。However, although the existing treatment methods are effective, they sometimes kill normal cells, the accuracy is not high enough, and there is room for improvement in the success rate of radical radiotherapy, and the dose distribution of anticancer drugs needs to be more refined. In addition, some particles in the existing method are harmful to the human body.
发明内容SUMMARY OF THE INVENTION
本发明的目的就在于为了解决上述问题而提供一种用于癌细胞的放射治疗方法。An object of the present invention is to provide a radiotherapy method for cancer cells in order to solve the above problems.
本发明通过以下技术方案来实现上述目的：一种用于癌细胞的放射治疗方法，包括以下步骤：The present invention achieves the above object through the following technical solutions: a radiotherapy method for cancer cells, comprising the following steps:
步骤一、放射性粒子制备，用生物相容性良好的高分子可降解材料作为基材进行制备；Step 1, preparation of radioactive particles, using a polymer degradable material with good biocompatibility as a base material for preparation;
步骤二、清洗，将制备好的放射性粒子用浓度为0.1-0.3mol/L的改性溶液进行浸泡清洗；Step 2, cleaning, soaking and cleaning the prepared radioactive particles with a modified solution with a concentration of 0.1-0.3 mol/L;
步骤三、偶联化，将清洗完的粒子放入到偶联剂内浸泡2小时；Step 3, coupling, put the cleaned particles into the coupling agent and soak for 2 hours;
步骤四、同位素标记，用将含有碘元素的溶液加入到步骤三内的溶液内对放射性粒子进行同位素标记；Step 4, isotope labeling, by adding the solution containing iodine element to the solution in step 3 to carry out isotope labeling on the radioactive particles;
步骤五、粒子注入患者体内，将获得的放射性粒子注入到患者的体内，并进行元素放射；Step 5. The particles are injected into the body of the patient, the obtained radioactive particles are injected into the body of the patient, and elemental radiation is performed;
步骤六、伽玛射线治疗，用机器发射伽玛射线对同位素标记的癌细胞进行灭杀。Step 6: Gamma-ray therapy, which uses a machine to emit gamma-rays to kill the isotope-labeled cancer cells.
作为本发明再进一步的方案：所述步骤一中，生物相容性良好的高分子可降解材料为聚乳酸和聚氨酯的混合共聚物。As a further solution of the present invention: in the first step, the polymer degradable material with good biocompatibility is a mixed copolymer of polylactic acid and polyurethane.
作为本发明再进一步的方案：所述步骤二中，表面改性溶液为壳聚糖-乙酸溶液，其中壳聚糖先与乙醇水溶液均匀混合，密封，使得壳聚糖充分膨胀，然后加入稀的醋酸溶液搅拌均匀，并静置一段时间。As a further solution of the present invention: in the second step, the surface modification solution is a chitosan-acetic acid solution, wherein the chitosan is uniformly mixed with the ethanol aqueous solution and sealed to make the chitosan fully swell, and then a dilute solution is added. The acetic acid solution was stirred evenly and allowed to stand for a while.
作为本发明再进一步的方案：所述步骤三中，偶联剂溶液为戊二醛水溶液，并在偶联化反应结束后加入含有碘元素的溶液去除游离的官能团。As a further scheme of the present invention: in the third step, the coupling agent solution is an aqueous solution of glutaraldehyde, and after the coupling reaction is completed, a solution containing iodine element is added to remove free functional groups.
作为本发明再进一步的方案：所述步骤四中，利用放射性同位素对步骤三中得到的粒子中碘元素进行置换。As a further solution of the present invention: in the fourth step, the iodine element in the particles obtained in the third step is replaced with a radioactive isotope.
本发明的有益效果是：该用于癌细胞的放射治疗方法设计合理：The beneficial effects of the present invention are: the radiotherapy method for cancer cells is reasonably designed:
1、采用与生物相容性较好的高分子可降解材料作为粒子基材，在注入人体内易分解，随着人的新陈代谢排除，减少对患者身体的损害，且保证基材在后续操作过程中结构的稳定性；1. Use polymer degradable material with good biocompatibility as the particle base material, which is easy to decompose when injected into the human body. With the elimination of human metabolism, the damage to the patient's body is reduced, and the base material is guaranteed in the subsequent operation process. the stability of the structure;
2、对制备的基材进行接枝清洗和偶联化反应，去除基材表面游离的官能团，便于放射性同位素对基材进行置换反应，从而确保其注入人体后会精准对癌细胞进行定位，方便伽玛射线的集中清理，提高该治疗方法的安全性，减少其对安全正常细胞灭杀的可能性，提高该方法的操作安全性，并在一定程度上减少患者体内癌细胞的残余量。2. Carry out graft cleaning and coupling reaction on the prepared substrate to remove the free functional groups on the surface of the substrate, which facilitates the replacement reaction of the substrate by radioisotopes, so as to ensure that the cancer cells will be accurately located after being injected into the human body, which is convenient and convenient. The centralized cleaning of gamma rays improves the safety of the treatment method, reduces the possibility of killing normal cells safely, improves the operational safety of the method, and reduces the residual amount of cancer cells in the patient to a certain extent.
附图说明Description of drawings
图1为本发明流程结构示意图。FIG. 1 is a schematic diagram of the flow structure of the present invention.
具体实施方式Detailed ways
下面将结合本发明实施例中的附图，对本发明实施例中的技术方案进行清楚、完整地描述，显然，所描述的实施例仅仅是本发明一部分实施例，而不是全部的实施例。基于本发明中的实施例，本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例，都属于本发明保护的范围。The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the accompanying drawings in the embodiments of the present invention. Obviously, the described embodiments are only a part of the embodiments of the present invention, but not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those of ordinary skill in the art without creative efforts shall fall within the protection scope of the present invention.
请参阅图1，一种用于癌细胞的放射治疗方法，包括以下步骤：Referring to Figure 1, a radiation therapy method for cancer cells includes the following steps:
步骤一、放射性粒子制备，用生物相容性良好的高分子可降解材料作为基材进行制备；Step 1, preparation of radioactive particles, using a polymer degradable material with good biocompatibility as a base material for preparation;
步骤二、清洗，将制备好的放射性粒子用浓度为0.1-0.3mol/L的改性溶液进行浸泡清洗；Step 2, cleaning, soaking and cleaning the prepared radioactive particles with a modified solution with a concentration of 0.1-0.3 mol/L;
步骤三、偶联化，将清洗完的粒子放入到偶联剂内浸泡2小时；Step 3, coupling, put the cleaned particles into the coupling agent and soak for 2 hours;
步骤四、同位素标记，用将含有碘元素的溶液加入到步骤三内的溶液内对放射性粒子进行同位素标记；Step 4, isotope labeling, by adding the solution containing iodine element to the solution in step 3 to carry out isotope labeling on the radioactive particles;
步骤五、粒子注入患者体内，将获得的放射性粒子注入到患者的体内，并进行元素放射；Step 5. The particles are injected into the body of the patient, the obtained radioactive particles are injected into the body of the patient, and elemental radiation is performed;
步骤六、伽玛射线治疗，用机器发射伽玛射线对同位素标记的癌细胞进行灭杀。Step 6: Gamma-ray therapy, which uses a machine to emit gamma-rays to kill the isotope-labeled cancer cells.
进一步的，在本发明实施例中，所述步骤一中，生物相容性良好的高分子可降解材料为聚乳酸和聚氨酯的混合共聚物，采用与生物相容性较好的高分子可降解材料作为粒子基材，在注入人体内易分解，随着人的新陈代谢排除，减少对患者身体的损害，且保证基材在后续操作过程中结构的稳定性。Further, in the embodiment of the present invention, in the step 1, the polymer degradable material with good biocompatibility is a mixed copolymer of polylactic acid and polyurethane, and the polymer degradable material with good biocompatibility is used. As a particle base material, the material is easily decomposed when injected into the human body. It is eliminated with the human metabolism, reducing the damage to the patient's body and ensuring the structural stability of the base material in the subsequent operation process.
进一步的，在本发明实施例中，所述步骤二中，表面改性溶液为壳聚糖-乙酸溶液，其中壳聚糖先与乙醇水溶液均匀混合，密封，使得壳聚糖充分膨胀，然后加入稀的醋酸溶液搅拌均匀，并静置一段时间，确保制备的基材纯度，并方便后续同位素之间的置换。Further, in the embodiment of the present invention, in the second step, the surface modification solution is a chitosan-acetic acid solution, wherein the chitosan is uniformly mixed with the ethanol aqueous solution and sealed to make the chitosan fully swell, and then the chitosan is added. The dilute acetic acid solution is stirred evenly and allowed to stand for a period of time to ensure the purity of the prepared substrate and facilitate subsequent substitution between isotopes.
进一步的，在本发明实施例中，所述步骤三中，偶联剂溶液为戊二醛水溶液，并在偶联化反应结束后加入含有碘元素的溶液去除游离的官能团，进一步去除基材表面的杂质，提高治疗方法的精准性。Further, in the embodiment of the present invention, in the third step, the coupling agent solution is an aqueous solution of glutaraldehyde, and after the coupling reaction is completed, a solution containing iodine element is added to remove free functional groups, and the surface of the substrate is further removed. impurities, improving the precision of the treatment method.
进一步的，在本发明实施例中，所述步骤四中，利用放射性同位素对步骤三中得到的粒子中碘元素进行置换，方便伽玛射线的集中清理，提高该治疗方法的安全性，减少其对安全正常细胞灭杀的可能性，提高该方法的操作安全性，并在一定程度上减少患者体内癌细胞的残余量。Further, in the embodiment of the present invention, in the fourth step, the iodine element in the particles obtained in the third step is replaced by radioisotopes, which facilitates the centralized cleaning of gamma rays, improves the safety of the treatment method, and reduces the The possibility of killing normal cells safely improves the operational safety of the method and reduces the residual amount of cancer cells in the patient to a certain extent.
工作原理：在使用该用于癌细胞的放射治疗方法时，首先制备放射性粒子的基材，然后用浓度为0.1-0.3mol/L的改性溶液进行浸泡清洗1-2小时，将清洗完的粒子放入到偶联剂溶液内继续浸泡两小时，浸泡结束后，用将含有碘元素的溶液加入到步骤三内的溶液内对放射性粒子进行同位素标记，将所得的基材粒子替换成具有放射性元素的粒子，然后注入人体内自行分解，寻找癌细胞，并进行射线灭杀。Working principle: When using the radiotherapy method for cancer cells, firstly prepare the base material of radioactive particles, and then soak and clean the modified solution with a concentration of 0.1-0.3mol/L for 1-2 hours, and the cleaned The particles are placed in the coupling agent solution and continue to be soaked for two hours. After the soaking, the radioactive particles are isotopically labeled by adding the solution containing iodine to the solution in step 3, and the obtained substrate particles are replaced with radioactive particles. The particles of the elements are then injected into the human body to decompose on their own, looking for cancer cells and killing them with radiation.
对于本领域技术人员而言，显然本发明不限于上述示范性实施例的细节，而且在不背离本发明的精神或基本特征的情况下，能够以其他的具体形式实现本发明。因此，无论从哪一点来看，均应将实施例看作是示范性的，而且是非限制性的，本发明的范围由所附权利要求而不是上述说明限定，因此旨在将落在权利要求的等同要件的含义和范围内的所有变化囊括在本发明内。不应将权利要求中的任何附图标记视为限制所涉及的权利要求。It will be apparent to those skilled in the art that the present invention is not limited to the details of the above-described exemplary embodiments, but that the present invention may be embodied in other specific forms without departing from the spirit or essential characteristics of the invention. Therefore, the embodiments are to be regarded in all respects as illustrative and not restrictive, and the scope of the invention is to be defined by the appended claims rather than the foregoing description, which are therefore intended to fall within the scope of the claims. All changes within the meaning and scope of the equivalents of , are included in the present invention. Any reference signs in the claims shall not be construed as limiting the involved claim.
此外，应当理解，虽然本说明书按照实施方式加以描述，但并非每个实施方式仅包含一个独立的技术方案，说明书的这种叙述方式仅仅是为清楚起见，本领域技术人员应当将说明书作为一个整体，各实施例中的技术方案也可以经适当组合，形成本领域技术人员可以理解的其他实施方式。In addition, it should be understood that although this specification is described in terms of embodiments, not each embodiment only includes an independent technical solution, and this description in the specification is only for the sake of clarity, and those skilled in the art should take the specification as a whole , the technical solutions in each embodiment can also be appropriately combined to form other implementations that can be understood by those skilled in the art.
Claims (5)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010196882.9A CN111514473A (en) | 2020-03-19 | 2020-03-19 | A method of radiation therapy for cancer cells |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010196882.9A CN111514473A (en) | 2020-03-19 | 2020-03-19 | A method of radiation therapy for cancer cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111514473A true CN111514473A (en) | 2020-08-11 |
Family
ID=71900393
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010196882.9A Pending CN111514473A (en) | 2020-03-19 | 2020-03-19 | A method of radiation therapy for cancer cells |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111514473A (en) |
-
2020
- 2020-03-19 CN CN202010196882.9A patent/CN111514473A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Knapp Jr | Rhenium-188-A generator-derived radioisotope for cancer therapy | |
| Dadachova et al. | Rhenium-188 as an alternative to Iodine-131 for treatment of breast tumors expressing the sodium/iodide symporter (NIS) | |
| EP1997532A1 (en) | Ophthalmic applicator for treatment of pterygium or glaucoma using 32-P alone or in combination with 103-Pd | |
| Ramamoorthy et al. | Production logistics and radionuclidic purity aspects of 153Sm for radionuclide therapy | |
| CN112843260A (en) | Medical radioactive silicon dioxide microsphere and preparation method and application thereof | |
| WO2018028643A1 (en) | Medical phosphorus-32 carbon microsphere and preparation method therefor | |
| CN111514473A (en) | A method of radiation therapy for cancer cells | |
| CN101068544B (en) | Radionuclide-chitosan complex having an improved stabilized gelatin in administering them to the body and their preparation method | |
| Li et al. | Preparation of 125I brachytherapy seeds by iodinating carbon bars with a silver coating | |
| CN110639033B (en) | A kind of visual radiation microsphere based on liquid metal and preparation method thereof | |
| CN114121330B (en) | Molybdenum technetium generator, preparation method and device | |
| WO2018028645A1 (en) | Medical yttrium-90 carbon microsphere, and preparation method therefor | |
| Castronovo et al. | System for sustained intravenous infusion of a sterile solution of 137mBa-ethylenediaminetetraacetic acid (EDTA) | |
| Oh et al. | Development of Actinium-225 Production Method using Liquid Target☆☆☆ | |
| Pourhabib et al. | Optimization of natural rhenium irradiation time to produce compositional radiopharmaceutical | |
| Zhou et al. | Clinically translatable phosphonated silica microspheres for selective internal radiation therapy of hepatocellular carcinoma | |
| Witcofski et al. | Correlation of Dose Rate and Biological Effect in Rat Liver Cells Resulting from X-Ray, 113mIn, and 198Au Irradiation | |
| US20220108813A1 (en) | Novel method to separate isotopes created by photonuclear reactions | |
| Saidi et al. | Application of Cyclotrons in Brachytherapy | |
| Sodikov et al. | Priority directions of nuclear medicine | |
| Wattar | Calculating the internal dose of radioiodine I-131 by OpenDose software based on Monte Carlo simulation | |
| CN117323448A (en) | Pharmaceutical composition containing radioactive microparticles and process for preparing same | |
| CN113873739A (en) | System based on proton irradiation Ni and preparation method of high-purity Ni target | |
| Witcofski et al. | FROM X-RAY, †œ3mIn, AND †98AuIRRADIATION | |
| Chie et al. | Exposure of the operator to ionizing radiation during intracoronary radiation therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200811 |
|
| RJ01 | Rejection of invention patent application after publication |